Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.

Some embodiments of the present invention relate to methods and compositions for assessing the absence, presence, progression, or stage of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.

The invention pertains to diagnosis and treatment of ovarian cancer (OC), cervical cancer (CC), or colorectal cancer (CRC). One embodiment of the invention provides a method of identifying OC, CC, or CRC based on the level of RHAMM in the urine of a subject. Another embodiment of the invention provides a method of identifying OC based on the level of

RHAMM in the urine and CA125 in the blood of a subject. The invention also pertains to monitoring the efficacy of a treatment of OC, CC, or CRC based on the level of RHAMM protein in the urine and/or the level of CA125 in the blood. Another embodiment of the invention provides devices and reagents to assay RHAMM in a urine sample and optionally, assay CA125 in a blood sample.

A fluorescence probe with mitochondrial targeting and two-photon property, its preparation method and application in detecting and tracking endogenous H.sub.2S in samples or living cells. The fluorescent probe is prepared by a four-step preparation method and demonstrates a UV-vis absorption increment .sub.ab=395 nm and 43 fold higher fluorescence intensity in the presence of H.sub.2S. The probe further demonstrates stability, selectivity for H.sub.2S over competing agents and sensitivity as low as 20 nm. A method of detecting endogenous H.sub.2S rapidly in the absence of any external stimulators is provided. Samples are contacted with the probe and the changes in fluorescence are monitored to detect H.sub.2S levels. The disclosed probe is non-toxic and suitable as a biomarker and therapeutic molecule in cancer and other diseases.

The invention relates to a microplate, an in vitro diagnostic kit for HPV type 16 E7 oncoprotein detection and a preparation method thereof. The in vitro diagnostic kit is comprised of a microplate pre-coated with an HPV type 16 E7 antibody and an HRP-labeled HPV type 16 E7 antibody with concentration of 0.05-0.4 g/ml, wherein the amount of the antibody in each microwell of the microplate is 0.05-0.5 g. The in vitro diagnostic kit is used for directly detecting the expression of high-risk HPV-associated oncoprotein and the expression level, and thus has a clear judgment on the infection degree of high-risk HPV, and facilitates subsequent treatment.

The present invention aims to provide a novel test method for evaluating the possibility of cervical cancer and a novel test reagent for use in the method. The present invention provides a test method for evaluating the possibility of cervical cancer, including the step of: detecting the MUC expression in a biological sample isolated from the uterine cervix.

In one aspect, methods of treating a subject having a cancer that expresses a cytokine receptor are provided. In some embodiments, the method comprises administering to the subject a biologic agent in an amount sufficient to induce loss of cytokine receptor signaling through increased expression of a Suppressor of Cytokine Signaling genes and/or loss of one or more cytokine receptor components from the cancer cell surface. In some embodiments, the biologic agent is a cytokine or cytokine mimetic.

The present invention relates to a diagnostic test for the detection of an E7 protein of a human papilloma virus in a biological sample wherein a sandwich ELISA as capture antibody at least two different rabbit monoclonal antibodies which bind to at least two different epitopes are used and as detection antibody at least two different polyclonal anti E7 antibodies are used.

The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.